Company Description:
Voyager Therapeutics is a Cambridge, MA based AAV gene therapy company focused on developing and delivering life-changing therapies to people living with severe neurological diseases, including Huntington’s Disease. We are planning to initiate VYTAL, a phase 1 clinical trial studying our single-dose gene therapy, by the end of 2021. Please contact us at clinicaltrials@vygr.com for more information.
Learn more:
Voyager Approach to Gene Therapy
